144 related articles for article (PubMed ID: 12429478)
1. Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.
Bouma M; Nuijen B; Sava G; Perbellini A; Flaibani A; van Steenbergen MJ; Talsma H; Kettenes-van den Bosch JJ; Bult A; Beijnen JH
Int J Pharm; 2002 Nov; 248(1-2):247-59. PubMed ID: 12429478
[TBL] [Abstract][Full Text] [Related]
2. A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.
Bouma M; Nuijen B; Jansen MT; Sava G; Flaibani A; Bult A; Beijnen JH
Int J Pharm; 2002 Nov; 248(1-2):239-46. PubMed ID: 12429477
[TBL] [Abstract][Full Text] [Related]
3. Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A.
Bouma M; Nuijen B; Jansen MT; Sava G; Bult A; Beijnen JH
J Pharm Biomed Anal; 2002 Nov; 30(4):1287-96. PubMed ID: 12408919
[TBL] [Abstract][Full Text] [Related]
4. Ruthenium antimetastatic agents.
Alessio E; Mestroni G; Bergamo A; Sava G
Curr Top Med Chem; 2004; 4(15):1525-35. PubMed ID: 15579094
[TBL] [Abstract][Full Text] [Related]
5. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.
Sava G; Bergamo A; Zorzet S; Gava B; Casarsa C; Cocchietto M; Furlani A; Scarcia V; Serli B; Iengo E; Alessio E; Mestroni G
Eur J Cancer; 2002 Feb; 38(3):427-35. PubMed ID: 11818210
[TBL] [Abstract][Full Text] [Related]
6. The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.
Bacac M; Hotze AC; van der Schilden K; Haasnoot JG; Pacor S; Alessio E; Sava G; Reedijk J
J Inorg Biochem; 2004 Feb; 98(2):402-12. PubMed ID: 14729322
[TBL] [Abstract][Full Text] [Related]
7. Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A.
Ravera M; Baracco S; Cassino C; Zanello P; Osella D
Dalton Trans; 2004 Aug; (15):2347-51. PubMed ID: 15278129
[TBL] [Abstract][Full Text] [Related]
8. Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A.
Bouma M; Nuijen B; Jansen MT; Sava G; Picotti F; Flaibani A; Bult A; Beijnen JH
J Pharm Biomed Anal; 2003 Feb; 31(2):215-28. PubMed ID: 12609661
[TBL] [Abstract][Full Text] [Related]
9. Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration.
Cocchietto M; Zorzet S; Sorc A; Sava G
Invest New Drugs; 2003 Feb; 21(1):55-62. PubMed ID: 12795530
[TBL] [Abstract][Full Text] [Related]
10. Fate of the antimetastatic ruthenium complex ImH [trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice.
Cocchietto M; Salerno G; Alessio E; Mestroni G; Sava G
Anticancer Res; 2000; 20(1A):197-202. PubMed ID: 10769655
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280.
Bouma M; Nuijen B; Harms R; Rice JR; Nowotnik DP; Stewart DR; Jansen BA; van Zutphen S; Reedijk J; van Steenbergen MJ; Talsma H; Bult A; Beijnen JH
Drug Dev Ind Pharm; 2003 Oct; 29(9):981-95. PubMed ID: 14606662
[TBL] [Abstract][Full Text] [Related]
12. Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.
Brescacin L; Masi A; Sava G; Bergamo A
J Biol Inorg Chem; 2015 Oct; 20(7):1163-73. PubMed ID: 26369538
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and X-ray Structural Analysis of the Ruthenium(III) Complex Na[trans-RuCl4(DMSO) (PyrDiaz)], the Diazene Derivative of Antitumor NAMI-Pyr.
Vajs J; Pevec A; Gazvoda M; Urankar D; Goreshnik E; Polanc S; Košmrlj J
Acta Chim Slov; 2017 Dec; 64(4):763-770. PubMed ID: 29318318
[TBL] [Abstract][Full Text] [Related]
14. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
[TBL] [Abstract][Full Text] [Related]
15. Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro.
Hostetter AA; Miranda ML; DeRose VJ; McFarlane Holman KL
J Biol Inorg Chem; 2011 Dec; 16(8):1177-85. PubMed ID: 21739255
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-selective inhibition of angiogenesis development by NAMI-A analogues.
Oszajca M; Collet G; Stochel G; Kieda C; Brindell M
Biometals; 2016 Dec; 29(6):1035-1046. PubMed ID: 27812766
[TBL] [Abstract][Full Text] [Related]
17. Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry.
Crul M; van den Bongard HJ; Tibben MM; van Tellingen O; Sava G; Schellens JH; Beijnen JH
Fresenius J Anal Chem; 2001 Mar; 369(5):442-5. PubMed ID: 11270226
[TBL] [Abstract][Full Text] [Related]
18. Interaction of apo-transferrin with anticancer ruthenium complexes NAMI-A and its reduced form.
Mazuryk O; Kurpiewska K; Lewiński K; Stochel G; Brindell M
J Inorg Biochem; 2012 Nov; 116():11-8. PubMed ID: 23010324
[TBL] [Abstract][Full Text] [Related]
19. Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c.
Casini A; Mastrobuoni G; Terenghi M; Gabbiani C; Monzani E; Moneti G; Casella L; Messori L
J Biol Inorg Chem; 2007 Nov; 12(8):1107-17. PubMed ID: 17680283
[TBL] [Abstract][Full Text] [Related]
20. A theoretical study on the hydrolysis process of the antimetastatic ruthenium(III) complex NAMI-A.
Chen J; Chen L; Liao S; Zheng K; Ji L
J Phys Chem B; 2007 Jul; 111(27):7862-9. PubMed ID: 17579393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
